Ones To Watch News
Refine Search
Biotechnology
Shares of US genetic meds company MeiraGTx Holdings were up 7% at $7.12 in early trading after it announced important developments along with its third-quarter 2024 financials, reporting a $0.54 per share loss. 13 November 2024
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Biotechnology
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover and develop novel treatments for Parkinson's disease, and another undisclosed neurodegenerative indication. 13 November 2024
Biotechnology
Neurogene has announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase I/II open-label trial designed to evaluate NGN-401 gene therapy for the treatment of female pediatric patients with Rett syndrome. 13 November 2024
Biotechnology
Sino-American oncology company BeiGene has announced third-quarter 2024 financials, showing the total revenues was $1,002 million, up 28% compared to $781 million in the same period of 2023. 13 November 2024
Biotechnology
Danish life sciences investor Novo Holdings is continuing the spread of its cash pile, this time as co-leader of a $181.4 million Series D financing in Alentis Therapeutics. 12 November 2024
Biotechnology
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Biotechnology
Norwegian clinical-stage biotech Nykode Therapeutics revealed that it has received notification from Genentech, a US subsidiary of Roche, of its decision to terminate the collaboration and licensing agreement for Nykode’s VB10.NEO cancer vaccine program. 12 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Biotechnology
The combination of Merck & Co’s Keytruda (pembrolizumab) and Citius Pharmaceuticals’ Lymphir (denileukin diftitox-cxdl) showed promising preliminary results in an investigator-initiated Phase I clinical trial for cancer patients with recurrent solid tumors. 11 November 2024
Pharmaceutical
Aurinia Pharmaceuticals has announced a major strategic overhaul, reducing its workforce by almost half to focus on driving Lupkynis (voclosporin) growth. 11 November 2024
Biotechnology
Privately-held Boston-based biopharma FogPharma has announced a name change and unveiled a new AI-based platform. 11 November 2024
Pharmaceutical
Viracta Therapeutics has announced a significant restructuring to prioritize its lead oncology candidate, nana-val (valganciclovir/valganciclovir sodium), aimed at treating certain people with peripheral T-cell lymphoma (PTCL). 8 November 2024
Biotechnology
US biotech venture fund Aditum Bio and China’s Leads Biolabs today announced the formation of Oblenio Bio, marking the thirteenth company launched by Aditum. 7 November 2024
Biotechnology
Oncology-focused biotech company Tango Therapeutics announced an update on its PRMT5 program. Tango noted that, based on positive data from the dose escalation and early dose expansion cohorts of the TNG462 Phase I/II clinical trial, it has selected TNG462 to move forward into full development. 7 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Pharmaceutical
PrognomiQ has announced a series D financing round of $34 million, led by Seer, bringing the firm’s total funding to over $135 million since its founding in September 2020. 6 November 2024
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) issued final guidance recommending reimbursement of Ayvakyt (avapritinib) from USA-based Blueprint Medicines. 6 November 2024
Pharmaceutical
Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with schizophrenia. 6 November 2024
Biotechnology
Sino-American biotech BeOne Medicines has announced financial results from the second quarter of 2025. 13 August 2025
Biotechnology
Texas, USA-based clinical-stage biotech Gameto, a clinical-stage biotechnology company developing stem cell-derived therapies for reproductive health, has announced the completion of a $44 million Series C financing. 13 August 2025
Pharmaceutical
The US Food and Drug Administration approved New Jersey, USA-based Insmed’s Brinsupri (brensocatib) tablets to treat non-cystic fibrosis bronchiectasis (NCFB), a chronic inflammatory lung condition, in patients ages 12 years and older. 13 August 2025
Biotechnology
Germany’s Bayer and privately-held Kumquat Biosciences, a US biotech founded by pioneers of the KRAS pathway, have entered into an exclusive global license and collaboration to develop and commercialize the US firm’s KRAS G12D inhibitor. 12 August 2025
Biotechnology
US biotech Rezo Therapeutics today announced the appointment of Derek Hicks as its chief executive (CEO). 12 August 2025
Biotechnology
UK and USA-listed PureTech Health today announced the launch of a new founded entity to be called Celea Therapeutics. 12 August 2025
Biotechnology
USA-based Bionova Scientific, a full-service contract development and manufacturing organization (CDMO) for biologics and a subsidiary of Japanese technology company Asahi Kasei, has announced the opening of a plasmid DNA (pDNA) development and production facility in The Woodlands, Texas. 12 August 2025
Biotechnology
French manufacturer Sartorius Stedim Biotech and Nanotein Technologies, a developer of next-generation immune cell activation reagents, have entered into a partnership. 11 August 2025
Biotechnology
Denmark-based IO Biotech’s shares traded 51% higher ahead of the morning bell at $2.74 after the company said that Cylembio (imsapepimut and etimupepimut 11 August 2025
Biotechnology
The US Food and Drug Administration (FDA) has ordered label changes for bluebird bio's Skysona (elivaldogene autotemcel) due to blood cancer risks associated with the gene therapy product. 11 August 2025
Biotechnology
Indian cell therapy company Eyestem Research has raised $10 million in a significantly oversubscribed funding round to support the next stage of development for its investigational retinal pigment epithelial (RPE) cell therapy, Eyecyte-RPE. 11 August 2025
Biotechnology
US clinical-stage biotech Vor Bio has announced the appointment of Dallan Murray as chief commercial officer, effective immediately. 11 August 2025
Pharmaceutical
USA-based biotech DoveTree Medicines has signed a far-reaching partnership with Chinese drug discovery company XtalPi, in a deal worth up to $5.99 billion. 7 August 2025
Biotechnology
US artificial intelligence drug discovery firm Chai Discovery has secured $70 million in Series A funding, drawing backing from several high-profile investors as it seeks to transform how new biologic drugs are engineered. 7 August 2025
Biotechnology
Shattuck Labs yesterday announced that it has entered into a securities purchase agreement for a private placement financing 6 August 2025
Biotechnology
US cardiometabolic specialist MetaVia has announced a research collaboration with Korea’s Syntekabio, an artificial intelligence (AI)-driven drug discovery company. 5 August 2025
Biotechnology
XOMA Royalty Corporation is to buy fellow US firm LAVA Therapeutics for $1.16 to $1.24 per share in cash, plus a contingent value right (CVR), the companies announced Monday. 5 August 2025
Biotechnology
Texas, USA-based Nanoscope Therapeutics has recently submitted a rolling biologics license application (BLA) to the Food and Drug Administration (FDA) for MCO-010 (sonpiretigene isteparvovec), a novel gene therapy candidate targeting retinitis pigmentosa (RP). 5 August 2025
Biotechnology
Privately-held US clinical-stage biotech Cellergy Pharma announced the appointment Christopher Cano as chief executive (CEO). 5 August 2025
Biotechnology
Swedish biotech Hansa Biopharma on Friday released encouraging top-line results from three patients with Duchenne muscular dystrophy (DMD) treated with Hansa’s imlifidase prior to receiving Sarepta Therapeutics’ Elevidys (delandistrogene moxeparvovec-rokl) in the SRP-9001-104 trial. 4 August 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze